Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial ongoing with estimated primary completion Feb 2026; no public results, topline readout, or efficacy data released as of April 2026. Sponsor site lists as Phase 2 active, enrollment nearing completion, no readout announced. ClinicalTrials.gov confirms active not recruiting, no results posted.
Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed85% confidenceGrok 4.20 (xAI)
Will the results be positive?
No public readout found. Trial (NCT02682511) is Active Not Recruiting with estimated primary completion Feb 2026; recent sponsor updates (Q4 2025) confirm enrollment complete and top-line expected later in 2026. No efficacy statements or results posted on ClinicalTrials.gov or in news.
Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:19 PM
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed96% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific public Phase 2 readout was found. ClinicalTrials.gov still shows NCT02682511 as active/not recruiting with estimated primary completion in February 2026, and sponsor updates in 2025-2026 describe the systemic sclerosis ifetroban study as still underway/near enrollment completion rather than reporting results.
Found Apr 3, 2026, 4:05 PMReviewed Apr 3, 2026, 4:47 PM
ClinicalTrialsclinicaltrials.govAug 1, 2025, 12:00 AM
Study Details | NCT02682511 | Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
ClinicalTrials.gov lists the Phase 2 study as Active, not recruiting, with estimated primary completion February 1, 2026; no posted study results/readout are shown.
Sponsorinvestor.cumberlandpharma.comMar 4, 2025, 12:00 AM
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
Sponsor said it approached the conclusion of enrollment in its systemic sclerosis Phase 2 study during 2024, indicating no trial-specific efficacy outcome was yet publicly reported.
Sponsorinvestor.cumberlandpharma.comMar 1, 2026, 12:00 AM
Cumberland Pharmaceuticals Reports 31% Fourth Quarter 2025 Revenue Growth
This 2026 sponsor update highlights positive DMD top-line results but says other ifetroban Phase 2 programs, including systemic sclerosis, are still underway, with no systemic-sclerosis readout disclosed.
NO_DECISIONDismissed88% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific public efficacy readout was found. Sponsor disclosures say the systemic sclerosis Phase 2 study had only recently completed enrollment/database work, and later said topline results for the diffuse cutaneous arm were merely expected by end-Q1 2026. That is insufficient to label this trial positive or negative.
Found Apr 1, 2026, 6:52 PMReviewed Apr 1, 2026, 7:03 PM